专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1997039745A1 USE OF INHALED RETINOIDS IN THE PREVENTION OF CANCER 审中-公开
标题翻译：在预防癌症中使用吸入反应物
公开(公告)号：WO1997039745A1
公开(公告)日：1997-10-30
申请号：PCT/US1997005409
申请日：1997-04-21
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , TONG, William, P. , WARRELL, Raymond, P.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K31/045
CPC分类号： A61K9/008 , A61K31/07 , A61K31/167 , A61K31/192 , A61K31/203 , A61K47/18
摘要： Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the prevention of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
摘要翻译：通过吸入来施用类维生素A来克服由全身给药引起的慢性毒性问题，并且可以使类视黄醇治疗作为预防呼吸道上皮癌，特别是与烟草使用有关的癌症的选择。类维生素A通过吸入个体的呼吸道作为空气传播组合物施用，其具有计量剂量气雾产生吸入器，其中类视黄醇溶解在药学上可接受的氯氟烃推进剂和烷基胺增溶剂的组合中。

2. 发明申请

WO1997034634A1 SINGLE CHAIN FV CONSTRUCTS OF ANTI-GANGLIOSIDE GD2 ANTIBODIES 审中-公开
标题翻译：抗链球菌GD2抗体的单链FV构建
公开(公告)号：WO1997034634A1
公开(公告)日：1997-09-25
申请号：PCT/US1997004427
申请日：1997-03-20
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , CHEUNG, Nai-Kong, V. , LARSON, Steven, M. , GUO, Hong-Fen , RIVLIN, Ken , SADELAIN, Michel
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K39/395
CPC分类号： C07K16/3084 , A61K47/6898 , A61K47/6899 , B82Y5/00 , C07K14/36 , C07K14/70517 , C07K16/30
摘要： Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-GD2 antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target GD2-producing tumor cells.
摘要翻译：重组抗体构建体包含抗GD2抗体的重链和轻链的可变区。这些抗体构建体可以偶联到诸如放射性标记的标记物或蛋白质例如链霉亲和素或前药转化酶，用于成像或治疗应用。抗体构建体也可以被转导入T细胞以产生靶向产生GD2的肿瘤细胞的T细胞群体。

3. 发明申请

WO1997027858A1 COMBINATION THERAPY METHOD FOR TREATING CANCER USING EDATREXATE AND A TAXANE DERIVATIVE, E.G. PACLITAXEL 审中-公开
标题翻译：用于治疗癌症的组合治疗方法和药物衍生物，E.G. 紫杉醇
公开(公告)号：WO1997027858A1
公开(公告)日：1997-08-07
申请号：PCT/US1997000947
申请日：1997-01-29
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , FENNELLY, David, W. , SIROTNAK, Francis, M.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K31/505
CPC分类号： A61K31/519 , A61K31/505 , A61K31/335 , A61K2300/00
摘要： This invention provides combination therapy methods, pharmaceutical combinations and compositions for inducing tumor cell regression in cancer patients, particularly metastatic breast cancer patients. The combination methods, combinations and compositions employ both edatrexate and a taxane (e.g. Paclitaxel) which are administered simultaneously or sequentially. The combination therapy described here permits the administration of unusually high doses of edatrexate.
摘要翻译：本发明提供了用于在癌症患者，特别是转移性乳腺癌患者中诱导肿瘤细胞退化的组合疗法，药物组合和组合物。组合方法，组合和组合物使用同时或顺序施用的依达曲斯和紫杉烷（例如紫杉醇）。这里描述的联合疗法允许施用异常高剂量的依达曲塞。

4. 发明申请

WO1997021729A1 METHODS AND COMPOSITIONS FOR MODULATING VESICLE RELEASE 审中-公开
标题翻译：调制VESICLE RELEASE的方法和组合物
公开(公告)号：WO1997021729A1
公开(公告)日：1997-06-19
申请号：PCT/US1996019661
申请日：1996-12-12
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SCHIAVO, Giampietro , ROTHMAN, James, E. , SÖLLNER, Thomas, H.
IPC分类号： C07K14/47
CPC分类号： C07K14/705 , C07K14/47 , C07K2319/00
摘要： This invention provides methods and compositions useful for modulating synaptic transmission. The compositions of this invention are complexes comprised of various combinations of proteins, such as tagmin, beta -SNAP, NSF, alpha -SNAP, and SNAREs involved in docking and fusion of synaptic vesicles to membranes. In addition, this invention relates to complexes of tagmin and special phospholipids (phosphatidyl inositols) which are a component of membranes involved in the secretory process. These complexes are useful for identifying other substances which may modulate synaptic transmission.
摘要翻译：本发明提供了可用于调节突触传递的方法和组合物。本发明的组合物是由各种蛋白质组合组成的复合物，例如tagmin，β-SNAP，NSF，α-NAP和涉及突触小泡与膜的对接和融合的SNARE。此外，本发明涉及tagmin和作为分泌过程涉及的膜的组分的特殊磷脂（磷脂酰肌醇）的复合物。这些复合物可用于鉴定可能调节突触传递的其他物质。

5. 发明申请

WO1997006821A1 HEAT SHOCK PROTEIN-BASED VACCINES AND IMMUNOTHERAPIES 审中-公开
标题翻译：基于热休克蛋白的疫苗和免疫治疗
公开(公告)号：WO1997006821A1
公开(公告)日：1997-02-27
申请号：PCT/US1996013363
申请日：1996-08-16
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , ROTHMAN, James, E. , HARTL, F., Ulrich , HOE, Mee, H. , HOUGHTON, Alan , TAKEUCHI, Yoshizumi , MAYHEW, Mark
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K39/00
CPC分类号： C07K7/06 , A61K38/00 , A61K39/0005 , A61K39/0011 , A61K39/02 , A61K39/12 , A61K47/646 , A61K47/65 , A61K47/6901 , A61K48/00 , A61K2039/5152 , A61K2039/5156 , A61K2039/53 , A61K2039/6043 , A61K2039/622 , A61K2039/625 , C07K7/08 , C07K14/47 , C12N2710/20034 , Y10S530/828
摘要： The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
摘要翻译：本发明涉及用于在受试者中诱导免疫应答的方法和组合物，其中所述受试者与一种或多种所定义的靶抗原组合施用有效量的至少一种热休克蛋白。这些方法和组合物可用于治疗感染性疾病和癌症。

6. 发明申请

WO1996034005A1 SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBR1 AND USES THEREOF 审中-公开
标题翻译：由单克隆抗体MBR1定义的与乳腺癌相关的抗原的合成及其用途
公开(公告)号：WO1996034005A1
公开(公告)日：1996-10-31
申请号：PCT/US1996006109
申请日：1996-04-26
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , DANISHEFSKY, Samuel, J. , BILODEAU, Mark, T. , HU, Shuang, Hua , PARK, Tae, Kyo , RANDOLPH, John, T. , KIM, In, Jong , LIVINGSTON, Philip, O.
IPC分类号： C07H15/24
CPC分类号： C07H15/10 , A61K38/00 , A61K39/0011 , C07H3/06 , C07H15/18 , C07H17/02 , C07K1/04 , C07K9/005 , C07K16/3015 , C07K16/44
摘要： The present invention provides a process for synthesizing a compound having structure (I), wherein R is H, as well as related oligosaccharides useful as a vaccine for inducing antibodies to human breast cancer cells in an adjuvant therapy therefor.
摘要翻译：本发明提供了用于合成具有结构（I）的化合物的方法，其中R是H，以及可用作用于在其辅助治疗中诱导人乳腺癌细胞的抗体的疫苗的相关寡糖。

7. 发明申请

WO1996002140A1 ISOLATED p27 PROTEIN AND METHODS FOR ITS PRODUCTION AND USE 审中-公开
标题翻译：分离的p27蛋白及其生产和使用的方法
公开(公告)号：WO1996002140A1
公开(公告)日：1996-02-01
申请号：PCT/US1995007361
申请日：1995-06-07
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , FRED HUTCHINSON CANCER RESEARCH CENTER , MASSAGUE, Joan , ROBERTS, James, M. , KOFF, Andrew , POLYAK, Kornelia
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , FRED HUTCHINSON CANCER RESEARCH CENTER
IPC分类号： A01N61/00
CPC分类号： C07K14/4738 , A61K38/00
摘要： An isolated protein designated p27 is disclosed. The p27 protein has an apparent molecular weight of about 27 kD, and is capable of binding to and inhibiting the activation of a cyclin E - Cdk2 complex. A nucleic acid sequence encoding p27 protein is disclosed, as well as a method for producing p27 in cultured cells. in vitro assays for discovering agents which effect the activity of p27 are also provided. Methods of diagnosing and treating hypoproliferative and hyperproliferative disorders are provided.
摘要翻译：公开了一种称为p27的分离的蛋白质。 p27蛋白具有约27kD的表观分子量，并且能够结合并抑制细胞周期蛋白E-Cdk2复合物的活化。公开了编码p27蛋白的核酸序列，以及培养细胞中p27的产生方法。还提供了影响p27活性的发现剂的体外测定。提供诊断和治疗低增殖和过度增殖性疾病的方法。

8. 发明申请

WO1994025570A1 METHOD FOR SCREENING FOR TARGETS FOR ANTI-INFLAMMATORY OR ANTI-ALLERGIC AGENTS 审中-公开
标题翻译：用于筛选抗炎剂或抗过敏剂的靶标的方法
公开(公告)号：WO1994025570A1
公开(公告)日：1994-11-10
申请号：PCT/US1994004466
申请日：1994-04-22
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , RAVETCH, Jeffrey, V. , KUROSAKI, Tomohiro
IPC分类号： C12N05/06
CPC分类号： G01N33/68 , A61K38/00 , C07K14/70535 , C12Q1/48 , G01N33/5047 , G01N33/564 , G01N33/56972 , G01N2333/70503 , G01N2500/00 , Y10S530/827
摘要： This invention provides a method for identifying a cellular protein capable of specifically binding to an activated antibody receptor, whose cytoplasmic domain comprising an ARH1 motif, comprising (a) obtaining cells comprising receptors having the ARH1 motif; (b) lysing the cells under conditions whereby the native complex of the receptor having the ARH1 motif and the cellular protein is preserved; (c) isolating the complex; and (d) testing the associated receptor and the protein for biochemical activities, thereby identifiying the cellular protein capable of specifically binding to an activated antibody receptor, whose cytoplasmic domain comprising an ARH1 motif. This invention further provides a method for identifying a cellular molecule capable of being a target for designing drugs for autoimmune disease, inflammation or allergy which comprises (a) contacting a cell lysate with a molecule having a motif of amino acid sequence, AENTITYSLLKHP (SEQ ID NO:1) under the conditions permitting formation of a complex between the cellular target molecule with the motif; (b) isolating the complex formed in step (a); and (c) testing the complex for biochemical activities, thereby identifying the cellular molecule capable of being a target for designing drugs for autoimmune disease, inflammation or allergy.
摘要翻译：本发明提供了一种用于鉴定能够特异性结合活化抗体受体的细胞蛋白质的方法，所述活化抗体受体的细胞质结构域包含ARH1基序，其包含（a）获得包含具有ARH1基序的受体的细胞; （b）在具有ARH1基序和细胞蛋白的受体的天然复合物被保留的条件下裂解细胞; （c）分离复合物; 和（d）测试相关受体和蛋白质的生物化学活性，从而鉴定能够特异性结合激活的抗体受体的细胞蛋白质，其活性抗体受体的胞质结构域包含ARH1基序。本发明还提供了鉴定能够成为用于设计自身免疫性疾病，炎症或变态反应的药物的靶标的细胞分子的方法，其包括（a）使细胞裂解物与具有氨基酸序列的基序的分子AENTITYSLLKHP（SEQ ID NO： NO：1）在允许细胞靶分子与基序形成复合物的条件下; （b）分离步骤（a）中形成的络合物; 和（c）测试复合物的生物化学活性，从而鉴定能够成为设计用于自身免疫性疾病，炎症或变态反应的药物的靶标的细胞分子。

9. 发明申请

WO1994020081A1 ANHYDRORETINOL AND DERIVATIVES THEREOF AS ANTAGONISTS 审中-公开
标题翻译： ANHYDRORTINOLOL及其衍生物作为拮抗剂
公开(公告)号：WO1994020081A1
公开(公告)日：1994-09-15
申请号：PCT/US1994002450
申请日：1994-03-08
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , HAMMERLING, Ulrich , BUCK, Jochen , DERGUINI, Fadila , NAKANISHI, Koji
IPC分类号： A61K31/015
CPC分类号： A61K31/07 , A61K31/015 , A61K31/045 , A61K31/075 , A61K31/22 , A61K31/23
摘要： This invention provides methods of inhibiting the growth of cells, of treating a subject having a disease characterized by an uncontrolled growth of cells and of blocking an immune response as well as related inflammatory responses in a subject which comprises administering a compound having structure (I).
摘要翻译：本发明提供了抑制细胞生长的方法，该方法包括给予具有结构（I）的化合物的方法，其治疗患有特征在于细胞不受控制的生长和阻断免疫应答以及相关炎症反应的疾病的受试者，。

10. 发明申请

WO1994008611A1 GROWTH HORMONE FRAGMENT hGH 108-129 审中-公开
标题翻译：生长HORMONE FRAGMENT hGH 108-129
公开(公告)号：WO1994008611A1
公开(公告)日：1994-04-28
申请号：PCT/US1993010088
申请日：1993-10-21
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SONENBERG, Martin
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K37/02
CPC分类号： C07K14/61 , A61K38/00
摘要： This invention provides a polypeptide having the sequence from the amino terminal to the carboxy terminal: Ser Asp Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly Ile Gln Thr Lwu Met Gly Arg Leu Glu.
摘要翻译：本发明提供了具有从氨基末端到羧基末端的序列的多肽：Ser Asp Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly Ile Gln Thr Lwu Met Gly Arg Leu Glu。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式